Clinical trial
Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06.
NCT00003407 is registered in ClinicalTrials.gov with Rush University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06.
- Lead sponsor
- Rush University Medical Center
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- February 13, 2001
- Completion date
- April 7, 2004
- Enrollment
- 0 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
drug/agent toxicity by tissue/organ, leukemia, myelodysplastic syndromes, neutropenia